AAIC 2025 Abstract
Clinical validation of Lumipulse G1200 automated immunoassays for Alzheimer's disease biomarkers in a Quebec cohort
Study in peopleBiomarkers
Abstract
Background: With the anticipated arrival of disease‐modifying treatments for Alzheimer’s disease (AD) in Canada, integrating biomarkers into clinical practice is crucial to enhancing diagnostic accuracy and optimizing referrals for treatment.
